Compare Gartner Inc (IT) vs TG Therapeutics Inc (TGTX) Price & Performance

Gartner (IT) trades at $141.06, up 0.62% today, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a net income margin of 11.44% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its leadership in Gartner Magic Quadrant reports, but an ongoing legal investigation adds uncertainty. Cash flow turned negative in 2025 due to high financing outflows, though revenue remains stable around $6.5 billion.

The outlook is cautiously optimistic with a consensus price target of $157.60 suggesting 12% upside. Key opportunities include steady revenue growth and high ROE of 94.88%, but risks involve the legal probe, elevated P/B ratio of 148.08, and volatile cash flows. Investors should weigh strong fundamentals against near-term headwinds.

TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.

The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.